摘要
贫血在肺癌患者中常见，其重要原因是由化疗所致。贫血可以引起乏力、心动过速等症状，影响患者的生活质量及疗效，导致生存时间缩短，被认为是判断预后的独立因素。输注红细胞、使用促红细胞生成类药物是目前治疗肺癌患者贫血的主要措施。在血红蛋白水平明显下降之前，以促红细胞生成类药物治疗为主，尽量减少输血次数，将血红蛋白水平维持在10．0—12．0g／dl之间，可改善患者生活质量，同时有效防止血栓形成等不良事件的发生。
Anemia is commonly observed in lung cancer patients, and it is mainly caused by chemo- therapy. Anemia can cause several debilitating symptoms such as fatigue and tachycardia which will not only influence the patients＇ quality of life and therapy effect, but also short the survival time. So anemia has been regarded as a poor independent prognostic indicator of the disease. Transfusion the erythrocytes and using the erythropoiesis stimulating agents is the main treatments of the disease. Using the erythropoiesis stimulatingagents is the main treatment before the hemoglobin decreasing significantly in order to reduce the times of trans- fusion. Keeping the hemoglobin between 10.0-12.0 g/dl can improve the patients＇ quality of life and avoid the adverse events such as thrombus formation at the same time.
出处
《国际肿瘤学杂志》
CAS
2013年第4期278-283,共6页
Journal of International Oncology
基金
浙江省医药卫生科技计划（20078025）
吴阶平医学基金（320.6750.11059、320.6750.11091、320.6799.1106）
关键词
贫血
肺肿瘤
治疗
Anemia
Lung neoplasms
Therapeutics
